Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Mafosfamide
Introduction
{{Chembox new
|ImageFile=Mafosfamide.svg
|ImageSize=
|IUPACName=2-{[2-[bis(2-chloroethyl)amino]-2-oxo-
1-oxa-3-aza-2λ5-phosphacyclohex-
4-yl}sulfanyl]ethanesulfonic acid
|OtherNames=
|Section1=Â ! colspan=2 style=”background: #f8eaba; text-align: center;” |Identifiers
|-
|
|
|-
|
|
|-
| ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field ‘wikibase’ (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field ‘wikibase’ (a nil value). |-
| MeSH | Mafosfamide |-
|
|
|-
| colspan=”2″ |
- C1COP(=O)(NC1SCCS(=O)(=O)O)N(CCCl)CCCl
|- |Section2=Â ! colspan=2 style=”background: #f8eaba; text-align: center;” |Properties
|-
|
| C9H19Cl2N2O5PS2
|- | Molar mass
| 401.269 g/mol
|- |Section3= }}’
Overview
Overview
Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. Several Phase I trials have been completed.[1][2]
References
References
- ↑ “Intrathecal Mafosfamide”. ClinicalTrials.gov. U.S. National Institutes of Health. August 21 2006. Retrieved 2007-07-13. Check date values in:
|date=(help) ClinicalTrials.gov Identifier NCT00062881. - ↑ “Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors”. ClinicalTrials.gov. U.S. National Institutes of Health. February 20 2007. Retrieved 2007-07-13. Check date values in:
|date=(help) ClinicalTrials.gov Identifier NCT00031928.